Virtually all people with Down syndrome develop brain changes associated with Alzheimer’s disease by age 40, and approximately 95% will go on to develop dementia due to Alzheimer’s, now the leading cause of death among adults with Down syndrome. John and Tami Marick understand firsthand the devastating effects Alzheimer’s disease has on loved ones, and the risk it poses to those with Down syndrome. The Maricks launched the JTMF Foundation in 2021 to fulfill a mission to improve the lives of people in need, including empowering individuals with intellectual and developmental disabilities. The Maricks fortuitously met Michael Rafii, MD, PhD, medical director of the USC Epstein Family Alzheimer’s Therapeutic Research Institute (ATRI) and principal investigator of the Alzheimer’s Clinical Trials Consortium – Down syndrome (ACTC-DS). As a result, the JTMF Foundation has expanded its footprint with a game-changing $3.3 million gift to USC to fund three main initiatives: funding five gold-standard Vanguard Clinical Trial Sites in the United States for four years; supporting the launch of a clinical trial site at Oregon Health & Science University (OSHU) to bring access to advances in Alzheimer’s treatments to individuals with Down syndrome in the area; and funding the first-of-its-kind Research Ambassador Program employing individuals with Down syndrome at clinical trial sites.

Researchers at Aarhus University have developed ear-EEG, a technology that enables long-term monitoring of brain activity and sleep in people's homes. Already being used in clinical studies, the technology could help detect diseases such as Parkinson’s and Alzheimer’s years earlier than today. The article explores how emerging health technologies are shifting healthcare from hospitals to homes, and why the next challenge is building healthcare systems that can use them.

Researchers have shown how an enzyme triggers cell stress and promotes the advance of Alzheimer’s disease in a self-perpetuating process. The team has developed an active ingredient that breaks this vicious circle. In mice treated with the substance, dementia advances much more slowly.

University of Florida researchers have developed an AI tool called AIDD that distinguishes between Alzheimer’s disease and dementia with Lewy bodies with near-perfect accuracy.